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Abstract
Epidemiological studies have shown that one of the strongest risk factors for prostate cancer is a family history of the
disease, suggesting that inherited factors play a major role in prostate cancer susceptibility. Germline mutations in BRCA2
predispose to breast and ovarian cancer with its predominant tumour suppressor function thought to be the repair of DNA
double-strand breaks. BRCA2 has also been implicated in prostate cancer etiology, but it is unclear the impact that
mutations in this gene have on prostate tumourigenesis. Here we have undertaken a genetic analysis in the mouse to
determine the role of Brca2 in the adult prostate. We show that deletion of Brca2 specifically in prostate epithelia results in
focal hyperplasia and low-grade prostate intraepithelial neoplasia (PIN) in animals over 12 months of age. Simultaneous
deletion of Brca2 and the tumour suppressor Trp53 in prostate epithelia gave rise to focal hyperplasia and atypical cells at 6
months, leading to high-grade PIN in animals from 12 months. Epithelial cells in these lesions show an increase in DNA
damage and have higher levels of proliferation, but also elevated apoptosis. Castration of Brca2;Trp53 mutant animals led to
regression of PIN lesions, but atypical cells persisted that continued to proliferate and express nuclear androgen receptor.
This study provides evidence that Brca2 can act as a tumour suppressor in the prostate, and the model we describe should
prove useful in the development of new therapeutic approaches.
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Introduction
Prostate cancer is the most common cancer in men in developed
countries, with a rising incidence of the disease. However, the
etiology of this malignancy is still unclear. Prostate cancer
progresses through a pathologically defined series of steps
involving increasing grades of PIN, invasive adenocarcinoma
and metastatic cancer [1]. Androgens are crucial for normal
prostate function, and act as pro-survival and proliferation factors
in cancer cells. As such, prostate cancer is sensitive to androgen
levels and androgen depletion therapy via chemical or surgical
castration is an initial step in treatment, typically resulting in
tumour regression. However, the cancer normally re-grows and
develops as a castration-independent tumour.
Epidemiological studies have shown that one of the strongest
risk factors for prostate cancer is a family history of the disease,
suggesting that inherited factors play a major role in prostate
cancer susceptibility [2,3]. Approximately 10% of prostate cancers
are thought to be hereditary, and this number increases with early
on-set disease. In spite of this, little is known about the mechanisms
of tumourigenesis of inherited prostate cancer. Prostate cancer
frequently clusters in families that have breast cancer, indicating a
genetic link between these two diseases [4–6]. Germline mutations
in BRCA2 predispose to both breast and ovarian cancer making it
a good candidate gene for prostate cancer etiology. There is an
increased risk of prostate cancer in individuals carrying a mutation
in BRCA2, particularly early-onset disease [7–10]. The Breast
Cancer Linkage Consortium found a significant relative risk of
4.65 for prostate cancer in male carriers of a deleterious BRCA2
mutation that rose to 7.33 in men under 65 years of age [7].
Consistent with this, analysis of men with early-onset disease
indicates that BRCA2 carriers account for between 0.8–2% of
prostate cancer cases, compared with the prevalence of 0.1%
BRCA2 mutations in the general population [11,12]. In addition,
BRCA2 mutation carriers have been associated with aggressive
prostate cancer [13–16].
BRCA2 is thought to act as a tumour suppressor, with tumours
arising from BRCA2 mutations frequently demonstrating loss-of-
heterozygosity with loss of the wild-type allele. BRCA2 plays an
important role in the repair of DNA double-strand breaks (DSB)
through homologous recombination (HR) [17]. When there is a
second identical DNA copy (i.e. the sister chromatid after
replication) HR is the primary method of repair and is a
relatively error-free DNA repair pathway. After DNA damage,
BRCA2 directly interacts with the recombinase RAD51, a
process that is essential for HR-mediated repair of DSBs [18].
When HR is defective or no sister chromatid is available the
error-prone methods of single-strand annealing and non-homol-
ogous end joining are used for DNA repair [19]. BRCA2-deficient
cells form chromosomal aberrations spontaneously in culture and
are more sensitive to certain DNA damaging agents [19–21].
Hence, loss of BRCA2 is thought to principally lead to tumour
progression by the failure to repair DNA by HR, leading to
genomic instability.
PLoS Genetics | www.plosgenetics.org 1 June 2010 | Volume 6 | Issue 6 | e1000995
Mouse models have shown a direct in vivo tumour suppressor
role for Brca2 in the mammary gland and have demonstrated a
synergistic tumour suppressor activity with Trp53. However, Brca2
heterozygous animals do not show a predisposition to tumour
formation and Brca2 null mice result in embryonic lethality
[18,22,23]. To circumvent this prenatal lethality, the Cre-LoxP
system has been used to conditionally delete Brca2 in a tissue-
specific manner. Deletion of Brca2 from the mouse mammary
epithelium either fails to produce mammary-gland tumours or
results in mammary-gland tumour formation with long latency
(1.4–1.6 years) [24–26]. Tumour latency was reduced in Brca2
mutant mice that were Trp53 heterozygous [24]. In addition, mice
with conditional inactivation of Brca2 and Trp53 developed
mammary tumours with high penetrance at 6 months [25].
To understand the role of Brca2 in prostate cancer we have used
a prostate–specific Cre line and a conditional Brca2 allele to delete
Brca2 in adult mouse prostate epithelia. We show that loss of Brca2
in the prostate results in focal hyperplasia and low-grade (LG) PIN.
Mice with conditional deletion of Brca2 and Trp53 have a high
incidence of high-grade (HG) PIN, which contain cells with
elevated DNA damage. PIN lesions in Brca2;Trp53 homozygous
mutant prostates persist and continue to proliferate after androgen
depletion. This work confirms the role of Brca2 as a tumour
suppressor in the prostate and provides a model to test potential
therapeutics in Brca2-deficient prostate neoplasia.
Results
Deletion of Brca2 from prostate epithelia results in
hyperplasia and low-grade PIN
To investigate the role of Brca2 in the prostate we deleted Brca2
from the adult mouse prostate epithelia. To achieve this we mated
mice carrying a Brca2 allele that has exon 11 flanked by loxP sites
(Brca2F/F) to transgenic mice carrying Cre recombinase under the
control of a prostate-specific composite rat probasin promoter,
PBCre4 [25,27]. This Cre line has been used successfully to delete
tumour suppressor genes and activate oncogenes to drive prostate
neoplasia and tumour progression [28–30]. Deletion of this Brca2
conditional allele results in the loss of a Rad51-interacting domain,
and consequently, homozygous germline deletion leads to
embryonic lethality [25].
Cohorts of male control (Brca2F/F), Brca2 heterozygous
(Brca2F/+;PBCre4) and Brca2 mutant (Brca2F/F;PBCre4) animals
were generated and analysed for tumour progression at 6 months,
10–14 months and 15–20 months of age. None of the Brca2F/+;
PBCre4 prostates had any observable morphological differences
compared to control prostates at any time point analysed (Figure 1
and Table 1). Focal hyperplasia that contained atypical cells was
first observed in Brca2F/F;PBCre4 prostates at 10–14 months and
was also present in these animals at 15–20 months (Table 1). In
addition, at 15–20 months a significant number of Brca2
homozygous mutant prostates had focal LG PIN in their lumen
compared to control animals (6/17 compared to 0/28; Z-test
p = 0.0001) (Figure 1A and Table 1). LG PIN lesions formed
characteristic tufting and cribiform patterns (Figure 1B). These
focal lesions contained multiple atypical cells that had prominent
nucleoli and hyperchromasia. Hyperplasia and LG PIN lesions
were present in all four prostatic lobes of Brca2 mutants.
Figure 1. Deletion of Brca2 from prostate epithelia results in
hyperplasia and LG PIN. (A) Haematoxylin and eosin stained sections
of dorsolateral prostate (DLP), ventral prostate (VP) and anterior
prostate (AP) of control and Brca2 mutants. Control (Brca2F/F) and
Brca2 heterozygous (Brca2F/+;PBCre4) prostates do not have PIN.
Prostate-specific homozygous deletion of Brca2 (Brca2F/F;PBCre4) results
in focal hyperplasia and LG PIN (indicated with arrows). Black box shows
the area shown in higher magnification in the panel below. (B) Detail of
LG PIN in the DLP of Brca2 mutant prostates. Left panel shows a lumen
with tufting pattern and right panel shows cribiform pattern.
Arrowheads indicate atypical cells.
doi:10.1371/journal.pgen.1000995.g001
Author Summary
In Western countries, prostate cancer is the most common
male cancer and the second biggest cause of cancer-
related deaths in men. Men with a familial history of either
breast or ovarian cancer have an elevated predisposition
to prostate cancer, suggesting there is a genetic element
to this disease. Indeed, the inheritance of a mutated form
of the breast cancer susceptibility gene BRCA2 has been
linked to the development of prostate cancer, although
the precise role that BRCA2 dysfunction plays in the
development of prostate cancer is unclear. To address this,
we have generated an animal model in which the mouse
Brca2 gene is specifically deleted in the adult prostate.
These mice develop precancerous prostate lesions, which
progress in severity and incidence with the loss-of-function
of an additional tumour suppressor, Trp53. Importantly,
blocking male steroidal hormone production by castration
leads to partial regression of the prostate lesions, however
cells continue to proliferate after androgen withdrawal.
This suggests human BRCA2 mutant prostate tumours, like
the majority of prostate cancers, will respond to hormone
therapy, but will relapse, as frequently occurs in this
disease. In summary, our model suggests that BRCA2 acts
as a tumour suppressor in the prostate and provides a pre-
invasive model to test novel therapeutics.
Brca2 Loss Leads to Mouse Prostate Tumourigenesis
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Combined deletion of Brca2 and Trp53 leads to frequent
high-grade PIN
The tumour suppressor TP53 is frequently mutated in BRCA2
cancers and studies in the mouse have shown a genetic interaction
between Brca2 and Trp53 [24,31,32]. To test if Brca2 and Trp53
cooperate in the prostate we deleted both of these genes in the
prostate epithelia using the PBCre4 transgene. Cohorts of male
control (Brca2F/F;Trp53F/F), Brca2 homozygous and Trp53 hetero-
zygous (Brca2F/F;Trp53F/+;PBCre4) and Brca2 and Trp53 double
homozygous (Brca2F/F;Trp53F/F;PBCre4) animals were generated
and analysed for tumour progression.
In addition to hyperplasia and LG PIN observed in Brca2
mutants, deletion of Brca2 and Trp53 resulted in the formation of
HG PIN lesions. At 10–14 months, Brca2F/F;Trp53F/+;PBCre4
animals had focal LG PIN and hyperplasia (Figure 2A and
Table 1). By 15–20 months, LG PIN was still present and a
significant number of animals had focal HG PIN compared to
control animals (6/15 compared to 0/28; Z-test p = 0.0017).
However, the frequency of HG PIN was significantly higher in
Brca2F/F;Trp53F/F;PBCre4 animals compared to Brca2F/F;Trp53F/+;
PBCre4 animals at this age (27/32 compared to 6/15; Z-test
p = 0.0058) (Figure 2A and Table 1). In these animals, focal areas
of hyperplasia consisting of atypical cells were present as early as 6
months. At 10–14 months, LG PIN was present and a significant
number of Brca2F/F;Trp53F/F;PBCre4 animals had HG PIN
compared to control animals (7/15 compared to 0/11; Z-test
p = 0.0276). Hyperplasia and LG PIN lesions were similar to those
found in Brca2F/F;PBCre4 mutants. Frequently multiple ducts of
each lobe had HG PIN, which were present in proximal and distal
regions of the prostate and consisted of many atypical cells filling
the lumen. Atypical cells were unorganised with poor orientation,
severe nuclear pleomorphism and abnormal nuclear to cytoplasm
ratios (Figure 2B). Mitotic figures, apoptotic bodies and areas of
necrosis were also present within HG PIN lesions (Figure 2B). In
some cases, epithelial cells of the lumen protrude into the adjacent
stroma and the smooth muscle surrounding the ducts was no
longer continuous but was broken up (Figure 2B). These areas
contained atypical smooth muscle cells and desmoplasia in the
surrounding stroma. HG PIN lesions were predominantly seen in
the anterior prostate (AP) and dorsal prostate (DP) of Brca2;Trp53
homozygous mutant animals, with a small number observed in
lateral and ventral lobes. Deletion of LoxP flanked Brca2 and
Trp53 alleles by the PBCre4 transgene in the prostate was
confirmed by PCR analysis on micro dissected tissue (Figure S1).
Brca2;Trp53 HG PIN lesions display increased DNA
damage and apoptosis
As the predominant tumour suppressor function of BRCA2 is
thought to be the repair of DNA DSBs, we assessed the level of
Table 1. The number of control, Brca2 mutant and
Brca2;Trp53 mutant prostates analysed and their phenotype.
Genotype Age Total Hyp LG PIN HG PIN
Control 6 months 4 0 0 0
10–14 months 11 0 0 0
15–20 months 28 2 0 0
Brca2F/+;PBCre4 12–20 months 7 1 0 0
Brca2F/F;PBCre4 6 months 2 0 0 0
10–14 months 4 2 0 0
15–20 months 17 10 6 0
Brca2F/F;Trp53F/+;PBCre4 6 months 2 0 0 0
10–14 months 10 7 2 0
15–20 months 15 11 8 6
Brca2F/F;Trp53F/F;PBCre4 6 months 3 2 0 0
10–14 months 15 12 9 7
15–19 months 32 30 29 27
Brca2 homozygous mutant prostates (Brca2F/F;PBCre4) have hyperplasia (Hyp) at
10–14 months and LG PIN at 15–20 months. Brca2 homozygous Trp53
heterozygous mutant prostates (Brca2F/F;Trp53F/+;PBCre4) have hyperplasia and
LG PIN at 10–14 months, and by 15–20 months have HG PIN. Brca2;Trp53
double homozygous mutant (Brca2F/F;Trp53F/F;PBCre4) prostates have
hyperplasia at 6 months and LG PIN at 10–14 months, and by 15–19 months
have a high incidence of LG PIN and HG PIN.
doi:10.1371/journal.pgen.1000995.t001
Figure 2. Combined deletion of Brca2 and Trp53 leads to HG
PIN. (A) Haematoxylin and eosin stained sections of dorsolateral
prostate (DLP), ventral prostate (VP) and anterior prostate (AP) of
Brca2;Trp53 mutants. Homozygous deletion of Brca2 and heterozygous
loss of Trp53 (Brca2F/F;Trp53F/+;PBCre4) in prostate epithelia results in
hyperplasia (indicated with white arrowhead) and PIN (indicated with
black arrow). Prostate-specific homozygous deletion of Brca2 and Trp53
(Brca2F/F;Trp53F/F;PBCre4) results in hyperplasia (indicated with black
arrowhead) and atypical cells at 6 months of age. Close-up in bottom
panel shows cluster of atypical cells. Brca2;Trp53 homozygous mutants
have focal HG PIN (indicated with yellow arrows). Black box shows the
area that is shown in higher magnification in the panel below. (B) Detail
of HG PIN in the AP of Brca2;Trp53 mutants. Left panel shows atypical
cells with arrows indicating severe pleomorphic nuclei. Middle panel
shows a mitotic figure (black arrowhead), apoptotic body (black arrow)
and an area of necrosis (white arrow). Right panel shows epithelial cells
protruding into broken-up atypical smooth muscle cells (black arrow)
and desmoplastic stroma (black arrowhead).
doi:10.1371/journal.pgen.1000995.g002
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spontaneous DNA damage in Brca2 and Brca2;Trp53 mutant
prostates. An early response to DNA damage is the phosphory-
lation of histone H2AX (cH2AX) [33]. Areas of hyperplasia and
PIN in Brca2 mutant and Brca2;Trp53 mutant prostates contained
cells that were positive for cH2AX, which were not present in
control prostates (Figure 3A). While Brca2F/F;PBCre4 and Brca2F/F;
Trp53F/+;PBCre4 LG PIN lesions had individual or small groups of
cH2AX positive cells, Brca2;Trp53 homozygous mutant prostates
had large focal areas with many positive cells. These areas of
cH2AX correlated with focal HG PIN lesions and were
predominantly present in the AP and DP.
Deletion of Brca2 frequently results in increased levels of cellular
apoptosis, presumably as a result of increased constitutive DNA
damage. To determine the level of apoptosis in prostate epithelia
after deletion of Brca2 and Trp53 we used the TUNEL assay, which
has been used to identify apoptosis in Brca2 null neural tissue [32].
Brca2mutant prostates showed a 3 fold increase in TUNEL positive
cells in areas of hyperplasia and LG PIN, compared to control
prostates that had few apoptotic cells (0.3% TUNEL positive cells vs
0.1% in control) (Figure 3B). A 4 fold increase in apoptosis was
observed in Brca2F/F;Trp53F/+;PBCre4 PIN foci (0.4% TUNEL
positive cells vs 0.1% in control). Notably, there was a 20 fold
increase in apoptotic cells in areas of HG PIN in Brca2;Trp53
homozygous mutant prostates (2% TUNEL positive cells vs 0.1% in
control) (Figure 3B). An anti-Caspase-3 antibody and histological
analysis confirmed that TUNEL positive cells were apoptotic and
not the result of labelling damaged DNA (data not shown).
Brca2;Trp53 mutant prostates have hallmarks of cancer
Ki-67 is a marker of proliferating cells and a prognostic
indicator in prostate cancer [34]. Analysis of Ki-67 showed a low
number of proliferating cells in control prostates that increased 6
fold in areas of hyperplasia and LG PIN in Brca2F/F;PBCre4
mutant prostates (2.2% Ki-67 positive cells vs 0.4% in control)
(Figure 4A). Levels of proliferation were 9 fold higher in Brca2F/F;
Trp53F/+;PBCre4 PIN lesions (3.5% Ki-67 positive cells vs 0.4%
in control), and dramatically increased by 30 fold in Brca2F/F;
Trp53F/F;PBCre4 HG PIN lesions (12% Ki-67 positive cells vs
0.4% in control) (Figure 4A).
Levels of the androgen receptor (AR) expressed in the luminal
epithelium usually increase in the nucleus during human prostate
carcinoma progression [35]. Brca2F/F;PBCre4 and Brca2F/F;Trp53F/+;
PBCre4 mutant prostates had increased AR expression in the
cytoplasm and nucleus of epithelial cells that correlated with regions
of LG PIN (Figure 4B). The level of AR increased significantly
more in Brca2F/F;Trp53F/F;PBCre4 HG PIN lesions where it was
found predominantly in the nucleus of luminal epithelial cells
(Figure 4B).
The human and mouse prostate comprise of basal, luminal and
rare neuroendocrine epithelial cells. In addition, intermediate or
transit amplifying (TA) cells are observed in human prostates [36].
Brca2;Trp53 homozygous mutant HG PIN lesions frequently
contained large groups of p63-expressing cells, a marker of basal
cells (Figure 4C). Instead of their normal flat shape and position
basal to the luminal cells, some p63-expressing cells were rounder
and in a position near the lumen of the prostate. Sections
fluorescently double labelled with p63 and the basal cell
cytokeratin CK5 confirmed the presence of clusters of aberrant
basal cells that protrude into the lumen (Figure 4D). Brca2;Trp53
homozygous mutant HG PIN lesions were then double labelled
with CK5 and CK8, a marker of differentiated luminal cells. Areas
of neoplasia showed an increase in CK8-expressing luminal cells
that were often adjacent to a population of expanded CK5-
expressing basal cells (Figure 4D). These regions occasionally had
cells that were labelled with both CK8 and CK5, similar to human
TA cells that co-express basal and luminal markers, which are not
seen in control mouse prostates (Figure 4D) [36].
Brca2;Trp53 PIN lesions proliferate post-castration
Androgen ablation is the standard treatment for human prostate
cancer. To assess the response of neoplasias formed after deletion
of Brca2 and Trp53 to androgen ablation, we surgically castrated
animals at 16 months when HG PIN lesions have already formed
and analysed them 4 days post-castration. Castration of control
animals resulted in normal prostate regression, with a reduction in
lumen size (Figure 5A). Brca2F/F;Trp53F/F;PBCre4 animals still
contained focal areas of neoplasia with atypical cells following
androgen-depletion (8/8 mutant animals) (Figure 5A). However,
we did not observe ducts with filled lumens as seen in areas of PIN
in non-castrated mutant animals.
Following castration of control male mice, AR is expressed at
low levels predominantly throughout the cytoplasm of luminal and
Figure 3. Brca2;Trp53 mutants have increased DNA damage and apoptosis. (A) Immunohistochemistry for cH2AX shows several cells have
DNA damage in LG PIN areas in Brca2F/F;PBCre4 and Brca2F/F;Trp53F/+;PBCre4 mutant prostates, whereas control (Brca2F/F) prostates have undetectable
levels of DNA damage. Brca2F/F;Trp53F/F;PBCre4mutants have multi-focal areas with a large number of cells with DNA damage in regions of HG PIN. (B)
TUNEL assay on sections of prostates demonstrates Brca2F/F;PBCre4 and Brca2F/F;Trp53F/+;PBCre4 mutant prostates have an increased level of
apoptosis, compared to control (Brca2F/F) prostates. The level of apoptotic cells increases further in HG PIN lesions of Brca2F/F;Trp53F/F;PBCre4 mutants.
Arrows indicate apoptotic cells. The anterior prostates of 16-month-old animals are shown.
doi:10.1371/journal.pgen.1000995.g003
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stromal cells (Figure 5B). Castration of Brca2F/F;Trp53F/F;PBCre4
animals resulted in AR expression in a diffuse pattern throughout
most prostate luminal and stromal cells (Figure 5B). However, AR
is expressed at higher levels in the nucleus of a small number of
cells in the PIN lesions of mutant animals post-castration
(Figure 5B).
A reduction in the level of circulating androgens results in
apoptosis of the AR-expressing luminal epithelial cells, normally
leading to initial prostate tumour regression. As expected, luminal
cells of control castrated animals contained apoptotic cells
throughout the prostate post-castration (Figure 5C). Castrated
Brca2;Trp53 homozygous mutants contained cells in all prostatic
lobes undergoing programmed cell death, including apoptotic cells
in PIN lesions (2.2% TUNEL positive cells vs 1.8% in castrated
control, p = 0.49) (Figure 5C).
Interestingly, Ki-67 staining showed an 18 fold increase in
proliferating cells in areas of neoplasia in Brca2;Trp53 mutants that
persisted after castration, compared to control castrated animals
(5.5% Ki-67 positive cells vs 0.3% in castrated control) (Figure 5D).
Discussion
Studies on human carriers of deleterious BRCA2 mutations have
implicated this gene in prostate cancer etiology, but its function in
this malignancy is unclear. We have undertaken a genetic analysis
of Brca2 function in the adult mouse prostate to define its role in
prostate cancer and to create an in vivo model of Brca2-dependent
prostate disease progression. Our study has demonstrated that loss
of Brca2 in the mouse prostate epithelium results in hyperplasia
and LG PIN. These lesions have an increase in the number of cells
with DNA damage and apoptotic cells, which could be the result
of the impairment of DNA repair pathways. This demonstrates not
only that Brca2 can play a role in the initiation of prostate
neoplasia but also that other factors are required for prostate
tumour progression.
Deletion of Brca2 and Trp53 in mouse prostate epithelia resulted
in a shorter latency and increased frequency of prostate neoplasia
compared to deletion of Brca2 alone (Figure 6). Moreover, the
severity of neoplasia increased in Brca2;Trp53 mutants, with the
formation of hyperplasia and LG PIN at initial stages followed by
a high incidence of multi-focal, proliferative HG PIN lesions with
progressive cellular atypia (Figure 6). HG PIN lesions that form
after deletion of Brca2 and Trp53 contained many cells with DNA
damage, indicating increased genomic instability [17]. Multi-focal
lesions are a common feature of human prostate cancer and may
be due to defects in the DNA damage response [37]. The
formation of HG PIN lesions in Brca2;Trp53 mutant prostates may
reflect the loss of key regulatory p53-dependent functions in
response to DNA damage controlling cell-cycle checkpoints,
apoptosis and senescence [38]. This demonstrates a co-operative
tumour suppressor function of Brca2 and Trp53 in the prostate
similar to the mammary gland [24–26].
A recent study investigating whether TP53 and BRCA2 are
frequently mutated together in human prostate cancer found that
TP53 overexpression could not distinguish BRCA2 carriers with
prostate cancer from a control group of prostate cancer cases [39].
Figure 4. Brca2;Trp53 mutant prostates have hallmarks of cancer. (A) Ki-67 immunohistochemistry shows increased proliferation in areas of
LG PIN in Brca2F/F;PBCre4 and Brca2F/F;Trp53F/+;PBCre4 mutant prostates, a low number of proliferating cells are present in control (Brca2F/F) prostates.
Brca2F/F;Trp53F/F;PBCre4 mutants have a large number of proliferating cells in areas of HG PIN. (B) AR immunohistochemistry demonstrating increased
levels of expression throughout the nucleus and cytoplasm in areas of LG PIN in Brca2F/F;PBCre4 and Brca2F/F;Trp53F/+;PBCre4 mutant prostates,
compared to control prostates (Brca2F/F). Brca2F/F;Trp53F/F;PBCre4 mutants have increased AR expression predominantly in the nucleus of cells in areas
of HG PIN. (C) p63 immunohistochemistry shows an increase in p63-expressing cells in HG PIN lesions in Brca2F/F;Trp53F/F;PBCre4mutant prostates and
normal expression in the basal cells of control (Brca2F/F;Trp53F/F) prostates. Arrows indicate a cluster of abnormal p63-expressing cells that are rounder
and nearer the lumen. (D) Left panel shows p63 (red) and CK5 (green) fluorescent immunohistochemistry analysis with labelled cells protruding into
the lumen (white arrowheads) in a region of PIN in Brca2F/F;Trp53F/F;PBCre4 mutants. Right panel shows CK5 (green, basal cells) and CK8 (red, luminal
cells) fluorescent immunohistochemistry with PIN lesions in Brca2F/F;Trp53F/F;PBCre4 mutants displaying an increase in luminal cells next to clusters of
basal cells. White arrowhead marks CK5 and CK8 double-labelled cells. DAPI nuclear stain is blue. The anterior prostates of 16-month-old animals are
shown.
doi:10.1371/journal.pgen.1000995.g004
Brca2 Loss Leads to Mouse Prostate Tumourigenesis
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However, this study was limited by the small number of BRCA2
cases and inability to detect TP53 mutations that do not stabilize
the protein, which are frequently detected in tumours with
impaired homologous recombination [40].
Deletion of Brca2 in other tissues frequently leads to an increase
in apoptosis, which is partially or fully rescued upon loss of Trp53
[31,32,41]. However, we see more apoptotic cells in Brca2;Trp53
mutant HG PIN lesions than in Brca2 mutant LG PIN lesions. The
increase in apoptosis in HG lesions could be due to the rapid
accumulation of additional mutations by proliferating cells, which
causes catastrophic amounts of DNA damage. This suggests that
while some Brca2-null cells may be rescued from apoptosis after
loss of Trp53, other cells in Brca2;Trp53 deficient HG neoplastic
lesions undergo p53-independent cell death. Several different
DNA damage-induced p53-independent mechanisms of apoptosis
have been reported in different cell types [42].
AR expression is increased in the nucleus of cells in Brca2;Trp53
HG PIN lesions suggesting they are androgen sensitive. Consistent
with this, castration of Brca2F/F;Trp53F/F;PBCre4 animals led to
regression of PIN and a reduction of cells within the lumen. This
suggests that BRCA2-driven prostate cancer would initially
respond to conventional androgen ablation. However, atypical
cells persist in Brca2;Trp53 HG PIN lesions that continue to
proliferate, indicating these lesions may be able to re-grow and
become castration-resistant. Interestingly, some cells in
Brca2;Trp53 mutant PIN lesions expressed AR at higher levels in
the nucleus after castration, indicative of active AR signalling.
Castration-resistant human prostate cancer growth commonly
remains AR-dependent and is thought to occur through several
mechanisms including AR amplification, AR mutation, changes in
AR co-regulators and growth factor activation [43]. The presence
of nuclear AR in castrated Brca2;Trp53 mutant prostates may
indicate the regulation of proliferation by this factor after
androgen depletion.
We often observed an increase in p63 positive basal cells, the
presence of TA-like cells and an adjacent expansion of luminal
cells in Brca2;Trp53 mutant HG PIN lesions. This suggests
increased proliferation of the basal cell population, with
maintenance of differentiation into luminal cells. Similarly,
deletion of the tumour suppressor Pten with the PBCre4 transgene
results in tumour formation with an increase in basal cells that
contain a progenitor cell sub-population, the presence of TA-like
Figure 5. Brca2;Trp53 PIN lesions proliferate post-castration. Control (Brca2F/F;Trp53F/F) and mutant Brca2F/F;Trp53F/F;PBCre4 prostates were
surgically castrated at 16 months and culled 4 days later. (A) Haematoxylin and eosin stain shows atypical cells are still present in Brca2F/F;Trp53F/F;
PBCre4 mutant prostates 4 days after castration, but there is a reduction in cells present in the lumen. Right panels show detail of neoplasia, atypical
cells are indicated with arrowheads. (B) AR immunohistochemistry shows expression 4 days post-castration is predominantly throughout the
cytoplasm of control and Brca2F/F;Trp53F/F;PBCre4 prostates. Arrows indicate cells that have higher nuclear AR expression. Right panels show detail of
cells with nuclear AR expression, indicated with arrowheads. (C) TUNEL assay analysis demonstrates an increase in apoptotic cells in control and
mutant prostates after castration. Arrows indicate some apoptotic cells. (D) Ki-67 immunohistochemistry shows there are proliferating cells in
castrated Brca2F/F;Trp53F/F;PBCre4 mutants. LP is lateral prostate, AP is anterior prostate.
doi:10.1371/journal.pgen.1000995.g005
Figure 6. Schematic showing the progression of prostate
neoplasia in Brca2 and Brca2;Trp53 mutant animals. Note that
prostate neoplasia onset is earlier and the severity of PIN increases in
Brca2 mutants as Trp53 is lost.
doi:10.1371/journal.pgen.1000995.g006
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cells and luminal cell differentiation [44]. The increase in basal
progenitor cell population could represent an expansion of cancer-
initiating cells, indicating that HG PIN lesions in Brca2;Trp53
mutant prostates may originate from these cells. Several other
murine models of prostate cancer that utilize the PBCre4 transgene
display increased and aberrant p63 expression during early stages
of cancer progression [29,30]. This transgene is expressed in both
the basal and luminal cells of the mouse prostate [44]. In contrast,
deletion of Pten using a PSA-driven Cre only expressed in luminal
cells results in cancer without an expansion in p63 cells [45].
However, this model has slower kinetics than the Pten; PBCre4
model and tumours are initiated from cells in the luminal epithelial
compartment. Frequently during human prostate tumour pro-
gression there is an increase in TA/progenitor cells, which has led
to the proposal that these cells could be tumour-initiating cells
[36,44,46]. Taken together, these data suggest that an increase in
the basal progenitor cells could be a common early event in
prostate neoplasia but may be dependent on the origin of the
cancer-initiating cell.
Although we frequently observed HG PIN lesions in
Brca2;Trp53 mutant prostates no invasive carcinoma formed. In
contrast, deletion of Brca2 and Trp53 in the mouse mammary
gland results in invasive carcinoma at 6 months, and consistent
with this, human carriers of BRCA2 mutations have a high-risk of
breast cancer. The lack of prostate carcinoma in our mutants may
reflect the relatively low penetrance of prostate cancer in human
BRCA2 mutation carriers and suggests there is only a subset of
BRCA2 carriers that develop aggressive forms of the disease [13–
16]. This subset may be dependent on additional genetic modifiers
or environmental factors that influence the risk of individuals
carrying a BRCA2 mutation forming prostate tumours [47]. It is
possible that human carriers of deleterious BRCA2 mutations
frequently form HG PIN lesions similar to our Brca2;Trp53 model
but that never progress to carcinoma and therefore go undetected.
Ongoing work into genetic modifiers of BRCA2may identify which
subgroups of patients with BRCA2 mutations are more at risk of
developing aggressive forms of the disease.
Variations in genetic background can have a modifying effect
on prostate tumour development in mice with tumour suppressor
deletions [48]. Due to the complex nature of mouse breeding we
were not able to investigate the effects of genetic background on
the prostate lesions observed in Brca2;Trp53 mutant mice in this
study. Although a change in genetic background may alter the
frequency of tumour phenotype, we only observed PIN in mutant
animals suggesting these lesions are an effect of Brca2 and Trp53
loss.
This murine study has demonstrated that deletion of the tumour
suppressor Brca2 results in LG PIN, with the additional loss of a
second tumour suppressor Trp53 leading to HG PIN. Other
mouse models of tumour suppressor gene loss result in varying
degrees of prostate tumour progression. Mice with prostate-
specific homozygous Pten deletion progress to invasive carcinoma
and metastasis [28]. The further loss of Trp53 in this model results
in a shorter latency to invasive carcinoma [49]. Deletion of Nkx3.1,
a gene involved in prostate epithelial cell differentiation, leads to
mice that develop epithelial hyperplasia and dysplastic lesions that
resemble human PIN, but do not progress to invasive carcinoma
[50,51].
Our pre-invasive model could be used in the future to test the
response to potential therapeutic agents and combination
therapies. For example, a recent synthetic lethal approach using
PARP inhibitors has been used successfully to specifically induce
cytotoxicity in HR-deficient cells [52]. Promising phase I clinical
data in BRCA2 carriers with a PARP inhibitor has shown
antitumour activity, including resolution of bone metastases in
one patient with prostate cancer [53]. These Brca2 mutant mice
may provide a useful model to examine cellular responses, such as
apoptosis, to combinations of therapies for optimisation of
treatment. In addition, this study demonstrates that Brca2 acts as
a tumour suppressor and can interact genetically with Trp53
deficiency in the prostate preventing DNA damage accumulation
and neoplasia progression.
Materials and Methods
Ethics statement
Animals were handled in strict accordance with UK Home
Office regulations.
Generation of prostate-specific Brca2 and Trp53 deletion
mice
Brca2F/F (targeting exon 11) mice and Trp53F/F (targeting exons
2–10) mice [25] and ARR2PBCre transgenic mice, PBCre4 [27],
have been previously described. The animals were bred on a
mixed genetic background.
Mouse prostate histology and statistical analysis
Histological phenotype of samples was assessed on haematox-
ylin and eosin stained sections. Serial sections were then stained for
immunohistochemical analysis. Histological assessment was based
on published guidelines and assisted by a pathologist [54,55]. PIN
lesions noted as LG were equivalent to PIN I-II and those noted as
HG were equivalent to PIN III-IV in Park et al [54]. The two-
sample Z-test was performed to test if there is a significant
difference between groups of animals.
Quantification of proliferation and cell death
Ki-67 or TUNEL staining was performed by immunohisto-
chemistry on sections and cells stained with nuclear brown DAB
chromogen were counted as positive. Cells from at least 4 high
power fields were counted per animal, which totalled more than
900 cells per animal. Five animals of each genotype were analysed.
Randomly selected fields were counted for control analysis and
sections corresponding to histologically identified areas of
hyperplasia and PIN were counted for mutant animals. All values
are significant with p,0.05 using Student t-test unless otherwise
stated.
Immunohistochemistry analysis
Antibody stains were done on paraffin sections as previously
described [56]. The following antibodies were used: Ki-67 (TEC-
3, Dako, 1:200 with amplification), AR (PG-21, Upstate, 1:250
with amplification), p63 (4A4, Santa Cruz Biotechnology, 1:200
with amplification, 1:50), cH2AX (JBW301, Upstate, 1:800 with
amplification), CK5 (PRB-160P, Covance, 1:50), CK8 (MMS-
162P, Covance, 1:200). The ABC elite vector kit was used for
amplification using biotinlyated secondary antibodies (Vector
Laboratories) and the DAB substrate (Dako). Secondary fluores-
cent antibodies were obtained from Molecular Probes and were
used at a 1:1000 dilution. TUNEL analysis was carried out using
the ApopTag apoptosis detection kit (Chemicon).
Supporting Information
Figure S1 Brca2 and Trp53 are deleted in mutant adult prostates.
PCR analysis of Cre, Brca2, and Trp53 on dissected anterior
prostate (AP), lateral prostate (LP), dorsal prostate (DP), and
ventral prostate (VP) tissue from a Brca2F/F;Trp53F/F (control) and
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Brca2F/F;Trp53F/F;PBCre4 (mutant) animal. Wild type (WT) and
water (H20) are controls.
Found at: doi:10.1371/journal.pgen.1000995.s001 (0.07 MB
DOC)
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